Supplementary Table 3. Cox regression analysis predicting death in the overall patients (Vp1-4) (n = 85)

Variable	Univariate analyses			Multivariate analyses		
	HR	95% CI	*p*-value	aHR	95% CI	*p*-value
RT	0.68	0.39-1.18	0.17	0.71	0.39-1.28	0.25
Age (years)	0.99	0.97-1.02	0.63	-	-	-
Male	0.54	0.29-1.00	0.05	-	-	-
Presence of cirrhosis	0.78	0.45-1.33	0.36	-	-	-
HBsAg positivity	1.19	0.68-2.09	0.54	-	-	-
Anti-HCV positivity	1.05	0.42-2.65	0.91	-	-	-
Alcohol use disorder	1.05	0.57-1.93	0.87	-	-	-
ALT (U/L)	1.00	0.99-1.01	0.93	-	-	-
AST (U/L)	1.00	1.00-1.01	0.000	1.00	1.00-1.01	0.02
Bilirubin (mg/dL)	1.81	1.23-2.66	0.003	1.57	0.95-2.57	0.08
Albumin (g/dL)	0.70	0.50-0.99	0.04	1.01	0.68-1.48	0.97
PT (INR)	4.08	0.24-69.74	0.33	-	-	-
$\log_e$AFP (ng/mL)	1.05	0.98-1.12	0.21	-	-	-
Tumor size > 10 cm	1.24	0.73-2.09	0.42	-	-	-
Multiple tumor nodules	1.23	0.70-2.15	0.47	-	-	-
Vp4	1.54	0.88-2.70	0.13	-	-	-
Hepatic vein invasion	2.21	0.88-5.57	0.09	-	-	-
Bile duct invasion	0.83	0.30-2.30	0.72	-	-	-
Distant metastasis	1.36	0.80-2.31	0.26	-	-	-
Previous locoregional therapy	0.94	0.55-1.59	0.81	-	-	-

HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; RT, radiation therapy; HBsAg, hepatitis B surface antibody; HCV, hepatitis C virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; INR, international normalized ratio; AFP, alpha-fetoprotein.